350 related articles for article (PubMed ID: 25945701)
1. Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.
Hol WG
Acta Crystallogr F Struct Biol Commun; 2015 May; 71(Pt 5):485-99. PubMed ID: 25945701
[TBL] [Abstract][Full Text] [Related]
2. Drug target identification in intracellular and extracellular protozoan parasites.
Müller J; Hemphill A
Curr Top Med Chem; 2011; 11(16):2029-38. PubMed ID: 21619514
[TBL] [Abstract][Full Text] [Related]
3. The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations.
Ogungbe IV; Setzer WN
Molecules; 2016 Oct; 21(10):. PubMed ID: 27775577
[TBL] [Abstract][Full Text] [Related]
4. Old Antiprotozoal Drugs: Are They Still Viable Options for Parasitic Infections or New Options for Other Diseases?
Cortez-Maya S; Moreno-Herrera A; Palos I; Rivera G
Curr Med Chem; 2020; 27(32):5403-5428. PubMed ID: 31264538
[TBL] [Abstract][Full Text] [Related]
5. Evolutionary relationships among protein lysine deacetylases of parasites causing neglected diseases.
Scholte LLS; Mourão MM; Pais FS; Melesina J; Robaa D; Volpini AC; Sippl W; Pierce RJ; Oliveira G; Nahum LA
Infect Genet Evol; 2017 Sep; 53():175-188. PubMed ID: 28506839
[TBL] [Abstract][Full Text] [Related]
6. Ultrastructural alterations in organelles of parasitic protozoa induced by different classes of metabolic inhibitors.
Rodrigues JC; de Souza W
Curr Pharm Des; 2008; 14(9):925-38. PubMed ID: 18473841
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug design.
Pizarro JC; Hills T; Senisterra G; Wernimont AK; Mackenzie C; Norcross NR; Ferguson MA; Wyatt PG; Gilbert IH; Hui R
PLoS Negl Trop Dis; 2013; 7(10):e2492. PubMed ID: 24147171
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?
Berg M; Van der Veken P; Goeminne A; Haemers A; Augustyns K
Curr Med Chem; 2010; 17(23):2456-81. PubMed ID: 20491648
[TBL] [Abstract][Full Text] [Related]
9. Selection of targets for drug development against protozoan parasites.
de Azevedo WF; Soares MB
Curr Drug Targets; 2009 Mar; 10(3):193-201. PubMed ID: 19275556
[TBL] [Abstract][Full Text] [Related]
10. Novel amidines and analogues as promising agents against intracellular parasites: a systematic review.
Soeiro MN; Werbovetz K; Boykin DW; Wilson WD; Wang MZ; Hemphill A
Parasitology; 2013 Jul; 140(8):929-51. PubMed ID: 23561006
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitizers in drug transport mechanisms involved in protozoan resistance.
Pradines B; Pagès JM; Barbe J
Curr Drug Targets Infect Disord; 2005 Dec; 5(4):411-31. PubMed ID: 16535862
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development.
Cavazzuti A; Paglietti G; Hunter WN; Gamarro F; Piras S; Loriga M; Allecca S; Corona P; McLuskey K; Tulloch L; Gibellini F; Ferrari S; Costi MP
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1448-53. PubMed ID: 18245389
[TBL] [Abstract][Full Text] [Related]
14. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation.
Hammarton TC; Mottram JC; Doerig C
Prog Cell Cycle Res; 2003; 5():91-101. PubMed ID: 14593704
[TBL] [Abstract][Full Text] [Related]
15. Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase.
D'Antonio EL; Deinema MS; Kearns SP; Frey TA; Tanghe S; Perry K; Roy TA; Gracz HS; Rodriguez A; D'Antonio J
Mol Biochem Parasitol; 2015 Dec; 204(2):64-76. PubMed ID: 26778112
[TBL] [Abstract][Full Text] [Related]
16. Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents.
Massai L; Messori L; Micale N; Schirmeister T; Maes L; Fregona D; Cinellu MA; Gabbiani C
Biometals; 2017 Apr; 30(2):313-320. PubMed ID: 28283781
[TBL] [Abstract][Full Text] [Related]
17. Protein kinases as targets for anti-parasitic chemotherapy.
Doerig C
Biochim Biophys Acta; 2004 Mar; 1697(1-2):155-68. PubMed ID: 15023358
[TBL] [Abstract][Full Text] [Related]
18. Typical 2-Cys peroxiredoxins in human parasites: Several physiological roles for a potential chemotherapy target.
Angelucci F; Miele AE; Ardini M; Boumis G; Saccoccia F; Bellelli A
Mol Biochem Parasitol; 2016; 206(1-2):2-12. PubMed ID: 27002228
[TBL] [Abstract][Full Text] [Related]
19. [Contemporary strategies and methods of modeling antiparasitic drugs].
Boczoń K
Wiad Parazytol; 1995; 41(1):43-52. PubMed ID: 7638963
[TBL] [Abstract][Full Text] [Related]
20. Parasite Polyamines as Pharmaceutical Targets.
Roberts S; Ullman B
Curr Pharm Des; 2017; 23(23):3325-3341. PubMed ID: 28571553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
